---
title: "BTIG Sticks to Their Buy Rating for Zevra Therapeutics (ZVRA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281777067.md"
description: "BTIG analyst Kambiz Yazdi has maintained a Buy rating for Zevra Therapeutics (ZVRA) with a price target of $23.00. Yazdi, a 4-star analyst with a 28.1% average return, focuses on the Healthcare sector. Additionally, Zevra received a Buy rating from TipRanks on April 3, while a Hold rating was reiterated by TipRanks – OpenAI on April 1."
datetime: "2026-04-06T15:45:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281777067.md)
  - [en](https://longbridge.com/en/news/281777067.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281777067.md)
---

# BTIG Sticks to Their Buy Rating for Zevra Therapeutics (ZVRA)

In a report released on April 2, Kambiz Yazdi from BTIG maintained a Buy rating on Zevra Therapeutics, with a price target of $23.00.

### Easter Sale - 70% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Yazdi is a 4-star analyst with an average return of 28.1% and a 56.76% success rate. Yazdi covers the Healthcare sector, focusing on stocks such as Sionna Therapeutics, Inc., vTv Therapeutics, and Zevra Therapeutics.

In addition to BTIG, Zevra Therapeutics also received a Buy from TipRanks – Google’s Google Biotechnology in a report issued on April 3. However, on April 1, TipRanks – OpenAI reiterated a Hold rating on Zevra Therapeutics (NASDAQ: ZVRA).

### Related Stocks

- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ZVRA.US](https://longbridge.com/en/quote/ZVRA.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study | DWTX Stock News](https://longbridge.com/en/news/286772955.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)